Present additional clinical data from the lower dose cohort of the AMT-130 study

Delivered by the deadline

AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.

Announced: 28 Feb 2022
Due: 30 Jun 2022
Delivered: 23 Jun 2022

Deadline
Met
Late
Not met
Today

What the company said

“Additional clinical data from all patients in lower dose cohort of U.S. Phase I/II study of AMT-130, including mHTT and NfL biomarkers, expected to be presented in second quarter of 2022”

SourceuniQure N.V. Form 8-K press release, 2022-02-28
FilingSEC filing index
Deadline as statedsecond quarter of 2022
Deadline used30 Jun 2022, the last day of the stated period
TypeProject
Permanent referenceKI-C-2022-QURE-001792
Cite as https://keptindex.org/c/KI-C-2022-QURE-001792/ — this address never changes.

What we found

Evidence strength A What the grades mean

The company announced safety and biomarker data from the lower-dose cohort of the U.S. Phase I/II study of AMT-130 on June 23, 2022, which is within the second quarter of 2022.

A
uniQure N.V. 8-K filed 2022-08-08 Regulatory filing · published 8 Aug 2022 · retrieved 1 Oct 2026 · kept permanently by the SEC
“In June 2022, initial 12-month observations were announced on the lower-dose cohort of the double-blinded and randomized U.S. Phase I/II study of AMT-130” ✓ confirmed on the page
A
uniQure N.V. 10-K filed 2023-02-27 Regulatory filing · published 27 Feb 2023 · retrieved 1 Oct 2026 · kept permanently by the SEC
“On June 23, 2022, we announced safety and biomarker data from the 10 patients enrolled in the low-dose cohort.” ✓ confirmed on the page

Market reaction: the shares moved -25.1% against the S&P 500 over the three sessions around the disclosure (5 Aug 2022 to 10 Aug 2022). What this measures

Checked 1 Oct 2026.

Commitment lineage

Every time the company restated this commitment. The original is never changed, and the outcome is always measured against version 1.

Deadline drift +549 days
2 versions

Version 1 · original · stated 28 Feb 2022

Deadline 30 Jun 2022 (“second quarter of 2022”) · wording expected
Version 2 · stated 27 Feb 2023

Deadline 31 Dec 2023 (“in the second half of 2023”) · wording expected

“Clinical data from the lower-dose cohort is expected to be presented in the second half of 2023”
Source for this version

Commitment DNA

The structured record of this commitment. Fields the company did not state are left blank rather than guessed.

Event type: Clinical readout
Indicative materiality: Medium rules
Action: Present
Deliverable: AMT-130 clinical data
Language: Expected (“expects”, “plans”)
In the company’s control: High
Specificity: High

How this entry was checked

Commitment recordedThe company's words were matched word for word against the filing.
First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.

Confirmed. This outcome counts towards the company's Kept Score. How verification works

Are you uniQure N.V.? You can publish an official statement next to this entry, free. Add a statement.

Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.